Friedemann Paul | BCTRIMS 2024 | Galoá Proceedings

Max Delbrück Center for Molecular Medicine

Friedemann Paul

Is this your profile? Do login to access your certificates

Efficacy and Safety of Inebilizumab in Patients 50 years of age and older with Neuromyelitis Optica Spectrum Disorder: N-MOmentum Study Subgroup Analysis
KANEGAE, Marilia ¹
MAO-DRAAYER, Yang ²
WINGERCHUK, Dean ³
GRAVES, Jennifer ⁴
KUNCHOK, Amy ⁵
LACKEY, Elijah ⁶
PAUL, Friedemann ⁷
FUJIHARA, Kazuo ⁸
SATO, Douglas Kazutoshi ⁹
WANG, Zhong ¹⁰
CIMBORA, Dan ¹⁰
PATTERSON, Kristina ¹⁰
CREE, Bruce ¹¹
¹ Amgen Inc. São Paulo, Brazil
² Oklahoma Medical Research Foundation
³ Mayo Clinic Health System
⁴ University of San Diego
⁵ Cleveland Clinic
⁶ Duke University Hospital
⁷ Max Delbrück Center for Molecular Medicine
⁸ Fukushima Medical University Hospital
⁹ Pontifical Catholic University of Rio Grande do Sul
¹⁰ Amgen (United States)
¹¹ University of California - San Francisco School of Medicine
-
305841

6. NMO, ADEM and CIS

Plataform presentation

Co-authors (12)

Publications in other proceedings

BCTRIMS 2023
Inebilizumab Reduces Attack Risk Independent of Low Affinity IgG Fc Region Receptor III-A Gene Polymorphisms in Neuromyelitis Optica Spectrum Disorder